Medtronic plc (NYSE: MDT) announced on April 20, 2026, that it has completed its acquisition of CathWorks, an Israeli-based medical technology company specializing in artificial intelligence (AI) for cardiovascular diagnostics. The transaction is valued at approximately $585 million, with additional undisclosed earn-out payments possible based on future performance milestones. This acquisition represents Medtronic’s second tuck-in transaction of 2026, following a strategic initiative to bolster its core business units through targeted technological integrations.
The closing allows Medtronic to fully integrate the CathWorks FFRangio System into its cardiovascular portfolio. The FFRangio technology utilizes advanced AI algorithms and computational science to provide a physiological assessment of coronary arteries from routine X-ray angiograms. Unlike traditional fractional flow reserve (FFR) assessments, which require invasive pressure wires and the administration of drugs to induce hyperemia, the FFRangio System is drug-free and wire-free. By automating the calculation of FFR, the platform assists interventional cardiologists in determining which lesions require percutaneous coronary intervention (PCI).
The completion of the deal follows the presentation of one-year results from the ALL-RISE landmark randomized control trial at the 2026 American College of Cardiology conference. The trial, which involved more than 1,900 patients across 59 global sites, demonstrated that the FFRangio System was non-inferior to traditional wire-based physiology in terms of major adverse cardiac events (MACE). The study also highlighted improved resource utilization and reduced procedure times when using the AI-driven approach.
Jason Weidman, senior vice president and president of the Coronary and Renal Denervation business at Medtronic, stated that the acquisition significantly enhances the company’s interventional cardiology offerings. Weidman noted that the integration of CathWorks’ technology provides physicians with data-driven insights to transform the catheterization laboratory and drive new standards of care. Ramin Mousavi, president and chief executive officer of CathWorks, added that the deal validates the shared vision of both companies to revolutionize cardiovascular diagnosis and patient outcomes.
The acquisition is the culmination of a multi-year strategic partnership that began in July 2022, when Medtronic made an initial $75 million investment in CathWorks and entered into a global co-promotion agreement. Medtronic confirmed that the financial impact of the transaction is expected to be immaterial to its fiscal year 2027 earnings per share and neutral to accretive thereafter. CathWorks, which was founded in Kfar Saba, Israel, will now be integrated into Medtronic’s Cardiovascular Portfolio. Medtronic, headquartered in Galway, Ireland, currently employs more than 95,000 people and operates in over 150 countries.